Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home

Administration of Ligilactobacillus Salivarius MP101 in an Elderly Nursing Home During the COVID Pandemics

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04922918

Acronym

PROBELDERLY

Enrollment

Registered

2021-06-11

Start date

2020-10-01

Completion date

2021-07-01

Last updated

2021-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

covid-19, elderly, nursing home, probiotics

Brief summary

The objective of this work was to investigate the effect of Ligilactobacillus salivarius MP101 on the functional (Barthel index), cognitive (GDS/FAST) and nutritional (MNA) status, and on the nasal and fecal inflammatory profiles of elderly living in a nursing home highly affected by COVID-19.

Interventions

BIOLOGICALLigilactobacillus salivarius MP101

Administration of the strain through a fermented milk

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

74 Years to 98 Years

Healthy volunteers

Yes

Inclusion criteria

* Living in the nursing home * Informed consent obtained

Exclusion criteria

* Absence of informed consent * Parenteral nutrition (exclusively) * Allergy to cow's milk protein

Design outcomes

Primary

Measure	Time frame	Description
Barthel index	4 months	functional status score (daily activities)
MNA score	4 months	Nutritional status
nasal and fecal immune profile	4 months	37-plex

Countries

Spain

Contacts

Primary ContactJuan Miguel Rodriguez, PhD

jmrodrig@ucm.es34913943749

Backup ContactLeonides Fernández, PhD

leonides@ucm.es34913943745

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026